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The clinical outcome of contralateral prophylactic mastectomy (CPM) in women with a BRCA1 or BRCA2 mutation and a personal
history of invasive breast cancer is unknown. We identified a cohort of 148 female BRCA1 or BRCA2 mutation carriers (115 and 33,
respectively) who previously were treated for unilateral invasive breast cancer stages I–IIIa. In all, 79 women underwent a CPM, while
the other women remained under intensive surveillance. The mean follow-up was 3.5 years and started at the time of CPM or at the
date of mutation testing, whichever came last, that is, on average 5 years after diagnosis of the first breast cancer. One woman
developed an invasive contralateral primary breast cancer after CPM, whereas six were observed in the surveillance group
(Po0.001). Contralateral prophylactic mastectomy reduced the risk of contralateral breast cancer by 91%, independent of the effect
of bilateral prophylactic oophorectomy (BPO). At 5 years follow-up, overall survival was 94% for the CPM group vs 77% for the
surveillance group (P¼0.03), but this was unexpectedly mostly due to higher mortality related with first breast cancer and ovarian
cancer in the surveillance group. After adjustment for BPO in a multivariate Cox analysis, the CPM effect on overall survival was no
longer significant. Our data show that CPM markedly reduces the risk of contralateral breast cancer among BRCA1 or BRCA2
mutation carriers with a history of breast cancer. Longer follow-up is needed to study the impact of CPM on contralateral breast
cancer-specific survival. The choice for CPM is highly correlated with that for BPO, while only BPO leads to a significant improvement
in overall survival so far.
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Women identified as carriers of a mutation in one of the breast
and ovarian cancer-susceptibility genes BRCA1 or BRCA2 have
strongly elevated risks of developing breast or ovarian cancer
(Ford et al, 1998). A recent meta-analysis (Antoniou et al, 2003)
including 22 studies, revealed an average cumulative risk of 65%
for breast cancer and 39% for ovarian cancer in BRCA1 mutation
carriers by age 70 years. The corresponding estimates for women
with a mutation in BRCA2 were 45 and 11%. Once diagnosed with
breast cancer, these women are also at high risk of developing
breast cancer in the contralateral breast. Early reports of The
Breast Cancer Linkage Consortium estimated a contralateral breast
cancer cumulative risk of 50–60% at age 70 years in BRCA1 or
BRCA2 mutation carriers (Easton et al, 1995; The Breast Cancer
Linkage Consortium, 1999). Later studies estimated even higher
incidences of contralateral breast cancer within the first 5 years of
follow-up after the primary breast cancer: 12–33% among BRCA1
or BRCA2 mutation carriers (2.4–6.5% per year) (Robson et al,
1998; Verhoog et al, 1998, 1999) as compared to a 0.4–1% per year
for breast cancer patients in general (Fisher et al, 1984).
Owing to the elevated risks and fear of contralateral breast
cancer, some women opt for contralateral prophylactic mastec-
tomy (CPM). No studies to date exist on the efficacy of CPM in
carriers of BRCA1 or BRCA2 mutations. Two retrospective studies
have evaluated a heterogenic population of breast cancer patients
with variable extent of family history and reported a reduction of
contralateral breast cancer after CPM, but without improvement of
overall survival in a follow-up period of 7–10 years (Peralta et al,
2000; McDonnell et al, 2001). A recent systematic review included
three additional studies; however, these lacked a comparison
group and/or follow-up was not standardised (Lostumbo et al,
2004). Therefore, in the present study, the efficacy of CPM was
investigated in a group of women with pathogenic BRCA1 or
BRCA2 mutations and a personal history of unilateral invasive
breast cancer.
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sPATIENTS AND METHODS
Identification of patients
All patients identified until June 2003 as being a BRCA1 or BRCA2
mutation carrier, with previous history of unilateral, stage I–IIIa,
invasive breast cancer, from The Netherlands Cancer Institute,
Amsterdam (n¼101) and The Leiden University Medical Centre,
Leiden (n¼47), were included. All women underwent surgery
for their primary breast cancer, either breast-conserving surgery
or mastectomy. In addition, all women were counselled and
monitored at the Family Cancer Clinic and outpatient clinic at each
institute. BRCA1 or BRCA2 mutation status was determined by
direct mutation testing. Women with so-called unclassified
variants were not included in this study. Data on mutation status,
date of disclosure DNA test result, pathological features and
treatment of the primary breast cancer as well as recurrence,
bilateral (prophylactic) (salpingo-)oophorectomy status (BPO),
other carcinomas, last date of follow-up and vital status were
extracted from medical files, operation and pathology reports.
Surgical techniques and surveillance
CPM was defined as surgical removal of the opposite breast in a
patient with previous unilateral invasive breast cancer, provided
that no suspicion for cancer in the opposite breast was apparent by
means of preoperative physical, radiological and, if applicable,
pathological examination. In case of a CPM, either a skin sparing
or a simple total mastectomy was performed. In women who
previously had undergone breast-conserving therapy for their
first breast cancer, a residual mastectomy procedure was carried
out on the ipsilateral breast at the time of CPM. In all cases, the
nipple–areolar complex was removed, while the pectoralis muscles
were preserved, except its fascia. Axillary node dissection was not
performed. However, in case of accidental removal of some
superficial axillary lymph nodes, these were examined histo-
logically. After CPM, women returned yearly for a physical
examination.
All CPM breast specimens were postoperatively examined for
lesions by experienced pathologists at each institution. Three
ductal carcinomas in situ and one 3.2cm large, invasive ductal
carcinoma Bloom & Richardson nuclear grade III were detected in
the specimens obtained at the time of prophylactic mastectomy.
Preoperative clinical or radiological assessment had not revealed
abnormalities.
According to Dutch guidelines, women with a BRCA1 or BRCA2
mutation are enrolled in the surveillance-screening program
from age 25 years. This is continued after a first breast cancer for
remaining breast tissue and the opposite breast. Regular surveil-
lance consisted of a monthly breast self-examination, semiannually
clinical breast examination and yearly mammography.
Statistical analysis
We addressed two main questions, first whether risk of
contralateral breast cancer was different between the surveillance
and CPM group, and second whether (contralateral) breast cancer
specific and overall survival differed between the groups. The start
of follow-up and inclusion criteria for analysis were chosen such
that the risk reduction of CPM for contralateral breast cancer
would not be overestimated (Klaren et al, 2003). Hence, the start
of follow-up was defined in the surveillance group as date of
mutation testing and in the CPM group as date of mutation testing
or CPM, whichever came last. In the surveillance group, mutation
testing was always performed after diagnosis of the first
breast cancer. In the CPM group, 15 patients were tested before
diagnosis of their first breast cancer; however, by definition the
date of CPM was taken as the start of follow-up. Only in 11
patients, the results of mutation analysis became available after
their CPM.
In the contralateral breast cancer risk analysis, patients in the
surveillance group who experienced contralateral breast cancer
before the date of mutation testing (n¼26) were excluded, as well
as four patients in the CPM group in whom in situ or invasive
carcinoma was detected at the time of prophylactic mastectomy.
Patient and treatment characteristics did not significantly differ
between patients who were kept in the contralateral breast cancer
risk analysis (n¼118 out of 148) and patients who were excluded
(n¼30), except that the latter had received less often chemo-
therapy (13.3 vs 53.5%, P¼0.001), had lower stage (53.3 vs 27.9%
stage I, P¼0.049), were diagnosed in earlier years (median 1990 vs
1994, P¼0.001) and had a longer delay between primary breast
cancer and date of mutation analysis (9.3 vs 5.3 years, P¼0.003).
The four patients excluded from the CPM group were all still alive.
Of the 26 patients, 24 excluded from the surveillance group were
still alive, one died of breast cancer and one died of ovarian cancer.
In the survival analysis, all patients, also the 26 patients with
contralateral breast cancer before the date of testing, were included.
w
2 tests, one-way ANOVA, Mann–Whitney U-tests and t-tests
were used to compare the patient characteristics. Kaplan–Meier
curves with log-rank test and Cox’s regression models were used to
evaluate the incidence of contralateral breast cancer and overall or
breast cancer-specific survival. In the Cox’s regression models, time
between first breast cancer and start of follow-up (to adjust for
survival bias), year of diagnosis first breast cancer, age at mutation
analysis, age at diagnosis first breast cancer, BPO, surgery (breast-
conserving surgery or mastectomy), chemotherapy, radiotherapy
and stage of first breast cancer were evaluated as confounders. If
the univariate estimate of the hazard ratio (HR) for CPM changed
more than 10% if a potential confounder was added to the model,
this factor was accepted as a confounder. A two-sided P-value of
o0.05 was considered to indicate statistical significance. All ana-
lyses were performed using SPSS Release 10.07 (Chicago, IL, USA).
RESULTS
Patient characteristics
The clinicopathological characteristics of the 148 women at time of
the primary breast cancer diagnosis are summarised in Table 1.
Eventually, 79 women opted for a CPM and 69 women remained
under close surveillance. The calendar year of first breast cancer
diagnosis was significantly later in the CPM group than in the
surveillance group, that is, 4 years.
The patient characteristics at the time of CPM and of women
under surveillance are listed in Table 2. The gene mutations in
BRCA1 or BRCA2 were equally distributed between the two groups.
The mean age at CPM was close to the mean age at mutation
analysis for this group with an average interval between the first
breast cancer diagnosis and CPM of 3.9 years, while women in the
surveillance group were on average tested at an older age. Women
with a CPM underwent more often an oophorectomy, especially
if considering BPO, and were significantly younger when they
underwent this surgical intervention than women in the surveillance
group. Considering the period from diagnosis of first breast cancer
until the end of follow-up (10.5 years in the surveillance group vs 7.4
years in the CPM group), in the complete surveillance group 32
contralateral breast cancers were observed, as compared to only one
in the CPM group (Table 3a). Recurrence of breast cancer did not
differ between the CPM and surveillance group (Table 3a).
Risk of contralateral breast cancer
For the analyses of contralateral breast cancer, follow-up started at
the date of mutation testing or the date of CPM, whatever came last
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s(see also Statistical analysis). The mean follow-up did not differ
markedly between both groups, 3.4 vs 3.1 years, respectively
(Table 3b). Six women (14%) in the surveillance group developed
contralateral breast cancer after a mean of 2.2 years follow-up
(mean interval 9.076.2 years after the first breast cancer
diagnosis). The one case of contralateral breast cancer observed
in the CPM group occurred in a 62-year-old woman 1.6 years after
the start of follow-up, and 5.4 years after the first breast cancer
diagnosis. A 1.8cm large, invasive ductal carcinoma grade III
(Bloom & Richardson) was detected in minimal residual mammary
gland tissue. At the end of the follow-up period, this woman was
still alive and had no evidence of disease.
The contralateral breast cancer-free survival in the CPM group
was significantly lower as compared to the women under
surveillance (log rank, P¼0.006) (Figure 1). Cox’s proportional-
hazards analysis showed that CPM significantly (P¼0.028)
Table 1 Clinicopathological characteristics of first breast cancer for
women who opted for CPM and women under surveillance
a
Characteristic
CPM group
(N¼79)
Surveillance
group
(N¼69) P-value
Age at first breast cancer (years)
Mean7s.e. 38.070.9 39.471.0 0.295
Range 26–56 25–64
Year of diagnosis
Mean 1995 1991 o0.001
Median 1997 1993
Range 1982–2002 1972–2002
Breast cancer stage
Stage I 32 (40.5) 25 (36.2) 0.324
Stage IIa 31 (39.2) 27 (39.1)
Stage IIb 10 (12.7) 15 (21.7)
Stage IIIa 6 (7.6) 2 (2.9)
Pathological T stage (cm)
T1: p2 43 (54.4) 38 (55.1) 0.677
T2: 2–5 33 (41.8) 30 (43.5)
T3: 45 3 (3.8) 1 (1.4)
Axillary status
Node negative 52 (65.8) 40 (58.0) 0.495
Node positive 27 (34.2) 29 (42.0)
Bloom & Richardson grade
Grade I — (0.0) 1 (2.1) 0.481
Grade II 22 (32.4) 16 (33.3)
Grade III 46 (67.6) 31 (64.6)
Morphology
Ductal 68 (89.5) 49 (75.4) 0.042
Other 8 (11.5) 16 (24.6)
Estrogen receptor status
Positive 15 (26.3) 17 (44.7) 0.078
Negative 42 (73.7) 21 (55.3)
Progesterone receptor status
Positive 12 (22.6) 12 (33.3) 0.332
Negative 41 (77.4) 24 (66.7)
Therapy
Breast-conserving surgery 21 (26.6) 41 (59.4) o0.001
Radiotherapy 46 (58.2) 58 (84.1) 0.001
Chemotherapy 46 (58.2) 26 (37.7) 0.014
Hormonal therapy 15 (19.0) 4 (5.8) 0.025
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean.
aValues represent N (%), unless stated otherwise.
Table 2 Characteristics of women who opted for CPM and women
under surveillance
Characteristic
CPM group
(N¼79)
Surveillance
group
(N¼69) P-value
Mutation status, N (%) 0.693
BRCA1 60 (75.9) 55 (79.7)
BRCA2 19 (24.1) 14 (20.3)
Age at mutation analysis (years)
Mean7s.e. 41.570.9 46.771.1 o0.001
Range 27–61 26–76
Age at CPM (years)
Mean7s.e. 41.970.9 NA
Range 27–61 NA
Bilateral (salpingo-
)oophorectomy, N (%)
63 (79.7) 46 (66.7) 0.092
Indication
Prophylactic 61 (96.8) 39 (84.8) 0.009
a
Ovarian carcinoma 2 (3.2) 4 (8.7)
Metastasis breast cancer in
ovary
— (0.0) 1 (2.2)
Adjuvant treatment first
breast cancer
— (0.0) 1 (2.2)
Radiologic castration — (0.0) 1 (2.2)
Age at bilateral prophylactic (salpingo-)oophorectomy (years)
Mean7s.e. 43.370.8 47.171.2 0.009
Range 30–60 35–64
Ipsilateral mastectomy (before
or at the start of follow-up)
79 (100) 34 (49.3) o0.001
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean;
NA¼not applicable.
aComparing prophylactic only.
Table 3a Outcome after first breast cancer in all patients in the CPM
and surveillance group
Outcome
CPM group
(N¼79)
Surveillance
group
(N¼69) P-value
Follow up after first breast cancer
mean7s.e. (years)
7.470.5 10.570.7 0.035
Contralateral breast cancer
N (%) 1
a (1.3) 32 (46.4) o0.001
Time until occurrence (years) 5.4 6.470.8
Vital status, N (%)
Alive, disease free 73 (92.4) 50 (72.5)
Alive, breast cancer 1 (1.3) 7 (10.1)
Alive, ovarian cancer 2 (2.5) 1 (1.4)
Deceased from breast cancer 3 (3.8) 8 (11.6)
Deceased from ovarian cancer — (0.0) 2 (2.9)
Deceased from other cancer — (0.0) 1 (1.4)
Recurrence, N (%)
Local recurrence 8 (10.1) 12 (17.4) 0.233
Regional recurrence 1 (1.3) 1 (1.4) 1.000
Distant metastasis 5 (6.3) 9 (13.0) 0.260
Interval between primary breast
carcinoma and start of follow-up
(Tables 3b and c)
4.070.5 6.870.7 0.001
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean.
aThree ductal carcinoma in situ and one invasive breast cancers found after
histological examination in the CPM were excluded.
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sdecreased the risk of contralateral breast cancer (HR 0.09 (95%
confidence interval (CI), 0.01–0.78)) (Table 4). Also within the
group of women with a BPO, the risk of contralateral breast cancer
was decreased after a CPM (3 vs 1 contralateral breast cancer in 39
women under surveillance and 61 women with CPM, respectively).
Breast cancer-specific and overall survival
In order to examine whether CPM prevented death from breast
cancer, breast cancer-specific and overall survival were compared
between the CPM and the surveillance group. The mean follow-up
did not differ markedly between both groups, 3.4 vs 3.7 years,
respectively (Table 3c). Most women in both groups died of breast
cancer (Table 3a and c). Breast cancer-specific survival (including
the first breast cancers) was not significantly better in the CPM
group (log rank, P¼0.11) (Figure 2). However, these were mostly
related to the first breast cancer as only one of them (in the
surveillance group) had developed a contralateral breast cancer.
Therefore, it was not possible to evaluate contralateral breast
cancer-specific survival. A significant overall survival advantage
was observed in the CPM group compared to the surveillance
group (log rank, P¼0.027) (Figure 3) due to three additional
events: two ovarian and one lung cancer. Multivariate Cox’s
proportional-hazards analysis showed that, after adjustment for
BPO (and time between first breast cancer and start follow-up
and chemotherapy treatment), women in the CPM group did not
significantly have better survival than those under surveillance
(overall mortality HR 0.35, P¼0.14) (Table 4). Patients who
underwent BPO had significantly better breast cancer specific (HR
0.15 (95% CI 0.04–0.51), P¼0.003) and overall survival (HR 0.14
(95% CI 0.05–0.41), Po0.0001) than patients who did not undergo
BPO. In multivariate analysis, with adjustment for CPM, time
between first breast cancer between first breast cancer and start
follow-up and chemotherapy, the breast cancer-specific survival
was no longer significant (HR 0.28 (95% CI 0.07–1.11), P¼0.07),
while the impact of BPO on overall survival remained (HR 0.23
(95% CI 0.07–0.78), P¼0.018). Having opted for both CPM and a
BPO resulted in a significantly better survival than surveillance
only (overall mortality HR 0.12 (0.03–0.46) and breast cancer-
specific mortality HR 0.16 (0.04–0.61), both adjusted for time
between first breast cancer and start follow-up and chemotherapy).
DISCUSSION
Women with a BRCA1 or BRCA2 mutation and a personal history
of breast cancer have high risks of developing contralateral breast
cancer. In this study, CPM reduced the risk for contralateral breast
cancer in BRCA1 or BRCA2 mutation carriers by 91%, independent
of the impact of BPO. Unadjusted overall survival was better for
the CPM group vs the surveillance group, but this was
Table 3b Contralateral breast cancer incidence after the start of follow-
up, which is at the date of mutation testing or date of CPM
Outcome and follow-up
CPM group
(N¼75)
Surveillance
group
(N¼43) P-value
Follow-up mean7s.e. (years)
Until contralateral breast
cancer, death or end of
follow-up
3.470.2 3.170.3 0.440
Contralateral breast cancer
N (%) 1
a (1.3) 6
b (14) 0.009
Time until occurrence (years) 1.6 2.270.8
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean.
aThree ductal carcinoma in situ and one invasive breast cancers found after
histological examination in the CPM were excluded.
bContralateral breast cancers
that occurred before the date of mutation testing (n¼26) were excluded.
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Figure 1 Contralateral breast cancer-free survival in patients who opted
for CPM vs patients who remained under surveillance.
Table 3c Vital status after the start of follow-up, which is at the date of
mutation testing or the date of CPM
Outcome and follow-up
CPM group
(N¼79)
Surveillance
group
(N¼69) P-value
Follow-up mean7s.e. (years)
Until death or end of follow-up 3.470.2 3.770.2 0.337
Vital status, N (%) (sum of
Table 3a)
0.021
Alive 76 (96.2) 58 (84.1)
Deceased 3 (3.8) 11 (15.9)
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean.
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Figure 2 Breast cancer-specific survival in patients who opted for CPM
vs patients who remained under surveillance.
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cancer-related events. In addition, after adjustment for BPO in a
multivariate Cox analysis, the CPM effect was no longer significant.
The observed impact of CPM on contralateral breast cancer
reduction is in agreement with studies on familial breast cancer.
McDonnell et al (2001) studied the efficacy of CPM in 745 women,
of whom 388 were premenopausal. They estimated a 90%
reduction after a median follow-up, from the date of CPM, of
10 years by using the Anderson model (Anderson and Badzioch,
1985) to predict contralateral breast cancer risk. Peralta et al
(2000) reported three contralateral breast cancers at the time of
prophylactic mastectomy in 64 women who underwent a CPM.
No other cases of contralateral breast cancer were observed after a
median follow-up, from the date of first breast cancer, of 6.2 years,
whereas 36 contralateral breast cancers occurred among 182 age-
matched controls after a median follow-up of 6.8 years. Despite a
significant improved disease-free survival (defined as the time to
any breast cancer event, whether recurrence or second primary),
these authors also could not observe an improved overall survival,
even though neither study adjusted for BPO status.
Bilateral prophylactic oophorectomy reduces the risk of first
breast cancer by approximately 50% and the risk of ovarian cancer
by almost 95% (Kauff et al, 2002; Rebbeck et al, 2002). In our
study, more women in the CPM group than in the surveillance
group had undergone BPO. Bilateral prophylactic oophorectomy
proved not to be a confounder in the contralateral breast cancer
risk analysis (Table 4); however, it was a strong confounder in the
survival analysis and clearly contributed to the difference in
survival between the CPM and surveillance group. In addition, the
impact of having opted for both CPM and a BPO vs surveillance
resulted in a larger survival benefit than having opted for CPM or
BPO alone.
Retrospective cohort studies considering breast cancer survival
in BRCA1 or BRCA2 mutation carriers may suffer from ascertain-
ment and testing bias. An ideal study design to evaluate the
efficacy of CPM would be a prospective, randomised clinical trial,
but such a trial is not feasible due to obvious ethical considera-
tions. In this retrospective study, we tried to avoid overestimation
of impact of the prophylactic procedure by testing and survival
bias, by starting the follow-up at the date of positive DNA test
result or date of CPM. By doing this, we excluded women from
the surveillance group who were triggered to be tested by their
diagnosis of contralateral breast cancer, precluding an over-
estimation of impact of the CPM (Klaren et al, 2003).
In the survival analyses, all patients were included, also the
possibly oversampled cases with contralateral breast cancer,
because they were still at risk at the date of testing. Their inclusion
might have resulted in a spuriously elevated breast cancer-specific
mortality. In our study, only two women who developed
contralateral breast cancer in the surveillance group died so far.
Therefore, we did not show an impact of CPM on survival in the
total cohort nor in the smaller cohort (n¼118) (overall survival in
CPM vs surveillance: 94 vs 68%, P¼0.0072; adjusted HR 0.31 (95%
CI, 0.07–1.38)).
Despite the bias adjustment described, some differences between
the groups remained: the CPM patients tended to come from
families with a more severe familial breast cancer history (data not
shown), were tested at a younger age and were tested more often
close to their first breast cancer diagnosis. The latter can partly be
logically explained because at average their breast cancer diagnosis
was in a later calendar period when testing was more widely
available already. In addition, patients coming from a family with a
more severe breast cancer history may be more eager to get tested.
However, these differences would lead to a higher background risk
for contralateral breast cancer and worse survival in the CPM
group and therefore might only strengthen our findings.
Even though stage did not differ between the groups, the
CPM group seemingly had chosen, besides more BPO, for more
aggressive therapy (chemotherapy, hormonal therapy and mas-
tectomy) for their first breast cancer compared to the surveillance
group. This difference in BPO and therapy might partly be
explained by the fact that the patients in the CPM group were
diagnosed in more recent calendar years and may partly be on
initiative of women themselves, who may have higher fear of breast
cancer because of their family history. The higher uptake of
bilateral mastectomy by women with a positive family history has
been supported by a study within a group of breast cancer patients
with an uninformative BRCA test result (Schwartz et al, 2004).
Although in our study women who opted for CPM had more often
undergone ipsilateral mastectomy than those in the surveillance
Table 4 Risk of contralateral breast cancer and overall survival of women under surveillance compared to women who opted for CPM
Univariate Multivariate
HR 95% CI P-value HR
a 95% CI P-value
Risk of contralateral breast cancer
b
CPM vs surveillance 0.09 0.01–0.78 0.03
Overall mortality
c
CPM versus surveillance 0.26 0.07–0.94 0.04 0.35
d 0.09–1.39 0.14
CPM¼contralateral prophylactic mastectomy; s.e.¼standard error of the mean; HR¼hazard ratio; CI¼confidence interval.
aHR derived from Cox’s proportional-hazards
analysis. Confounders (see Statistical analysis) were included if they changed the HR estimate by more than 10%.
bN¼118 patients.
cN¼148 patients.
dAdjusted for BPO, time
between first breast cancer and the start of follow-up, and chemotherapy.
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Figure 3 Overall survival in patients who opted for CPM vs patients who
remained under surveillance.
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sgroup (73 vs 41%), this did not have an impact on breast cancer-
specific or overall survival (data not shown). Adjuvant chemo-
therapy has been associated with a decreased rate of contralateral
breast cancer for breast cancer patients in general (Early Breast
Cancer Trialists’ Collaborative Group, 2001). In our study,
however, neither chemotherapy nor mastectomy had confounding
effects in the relation of CPM with contralateral breast cancer
incidence. The low participation of tamoxifen use by the women in
our study might be explained by their relatively young age as
well as the year of their first breast cancer diagnosis, because the
tamoxifen trials were mostly directed to postmenopausal women
and the results published after the date at first breast cancer
diagnosis in this population.
In summary, women with a BRCA1 or BRCA2 gene mutation
and a history of unilateral invasive breast cancer are at increased
risk for developing a primary contralateral breast cancer. This
study shows that CPM significantly reduces the risk for
contralateral cancer among BRCA1 or BRCA2 mutation carriers.
In addition, after 5-year follow up, overall survival was better
for the CPM group vs the surveillance group (P¼0.03), but
unexpectedly this was mainly due to the first breast cancer or other
cancer-related events. After adjustment for BPO in a multivariate
Cox analysis, the CPM effect was no longer significant. The choice
for CPM is highly correlated with that for BPO, while only BPO
leads to a significant improvement in overall survival so far. We do
expect, considering the numbers of women with contralateral
breast cancer in the surveillance group, that with longer follow-up
CPM will be shown to improve contralateral breast cancer-specific
survival. The choice for CPM must be seen within the context of
other preventive measures in survival, such as BPO, tamoxifen use
(Narod et al, 2000) and close surveillance.
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